Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback